The short version
Tirzepatide is a medication that acts on two hormone receptors — GLP-1 and GIP — rather than just one. It's administered by injection on a schedule a provider determines.
What it is
Tirzepatide is sometimes described as a "dual" agonist because it's designed to act on receptors for both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — two hormones involved in blood sugar regulation and appetite. That's the main structural difference from single-pathway GLP-1 medications like semaglutide.
How it's generally used
Like semaglutide, tirzepatide for weight management is typically:
- Administered by subcutaneous injection, usually on a weekly schedule.
- Started at a lower dose, which a provider may adjust over time.
- Used as part of a broader plan that includes nutrition and physical activity, not as a standalone approach.
The specific starting dose, adjustment schedule, and maximum dose are clinical decisions made between a patient and their provider.
Who typically discusses it with a provider
As with other GLP-1-class medications, people typically raise tirzepatide with a provider when exploring weight-management options. A clinician will look at overall health history, current medications, and weight-related health measures — not BMI in isolation — before determining whether it's an appropriate option to discuss further.
What the experience tends to involve
The adjustment period, the way a provider monitors dosing changes, and the kinds of side effects that are typically discussed are broadly similar to other GLP-1-class medications, though not identical. See what happens when you start a GLP-1 for a general overview, and common GLP-1 side effects for what's typically discussed before starting.
Where to go from here
If you're weighing tirzepatide against semaglutide, semaglutide vs. tirzepatide lays out the differences side by side.